MX2023004023A - Polipéptidos que eligen como objetivo a sars-cov-2 y composiciones y métodos relacionados. - Google Patents
Polipéptidos que eligen como objetivo a sars-cov-2 y composiciones y métodos relacionados.Info
- Publication number
- MX2023004023A MX2023004023A MX2023004023A MX2023004023A MX2023004023A MX 2023004023 A MX2023004023 A MX 2023004023A MX 2023004023 A MX2023004023 A MX 2023004023A MX 2023004023 A MX2023004023 A MX 2023004023A MX 2023004023 A MX2023004023 A MX 2023004023A
- Authority
- MX
- Mexico
- Prior art keywords
- cov
- methods
- sars
- nanocage
- related compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063089782P | 2020-10-09 | 2020-10-09 | |
| US202163197236P | 2021-06-04 | 2021-06-04 | |
| US202163220929P | 2021-07-12 | 2021-07-12 | |
| PCT/CA2021/051426 WO2022073138A1 (en) | 2020-10-09 | 2021-10-08 | Polypeptides targeting sars-cov-2 and related compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004023A true MX2023004023A (es) | 2023-07-07 |
Family
ID=81126329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004023A MX2023004023A (es) | 2020-10-09 | 2021-10-08 | Polipéptidos que eligen como objetivo a sars-cov-2 y composiciones y métodos relacionados. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250263469A1 (enExample) |
| EP (1) | EP4225804A4 (enExample) |
| JP (1) | JP2023544211A (enExample) |
| KR (1) | KR20230083316A (enExample) |
| AU (1) | AU2021356355A1 (enExample) |
| BR (1) | BR112023006497A2 (enExample) |
| CA (1) | CA3197642A1 (enExample) |
| MX (1) | MX2023004023A (enExample) |
| WO (1) | WO2022073138A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022160057A1 (en) * | 2021-01-28 | 2022-08-04 | The Hospital For Sick Children | Multabody constructs, compositions, and methods |
| WO2023035056A1 (en) * | 2021-07-12 | 2023-03-16 | The Hospital For Sick Children | Optimized multabody constructs, compositions, and methods |
| WO2024082067A1 (en) * | 2022-10-21 | 2024-04-25 | The Hospital For Sick Children | Multabody constructs, compositions, and methods targeting sarbecoviruses |
| WO2024085723A1 (ko) * | 2022-10-21 | 2024-04-25 | 충남대학교 산학협력단 | SARS-CoV-2 S1 유래 단백질 및 항체 Fc 영역 단백질을 표면에 동시에 디스플레이하는 페리틴 단백질 구조체 및 이의 코로나바이러스 SARS-CoV-2에 대한 백신 용도 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2780221A1 (en) * | 2009-11-04 | 2011-05-12 | Fabrus Llc | Methods for affinity maturation-based antibody optimization |
| CA2876099A1 (en) * | 2012-08-02 | 2014-02-06 | F. Hoffmann-La Roche Ag | Method for producing monomeric and multimeric molecules and uses thereof |
| WO2015109212A1 (en) * | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
| PT3215528T (pt) * | 2014-11-06 | 2019-10-11 | Hoffmann La Roche | Variantes da região fc com ligação modificada ao fcrn e métodos de utilização |
| WO2017196847A1 (en) * | 2016-05-10 | 2017-11-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens |
| SG11201900500TA (en) * | 2016-07-22 | 2019-02-27 | Dana Farber Cancer Inst Inc | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof |
| DK3661968T3 (da) * | 2017-08-04 | 2022-06-20 | Hospital For Sick Children | Nanopartikelplatform til antistof- og vaccineindgivelse |
| WO2021045836A1 (en) * | 2020-04-02 | 2021-03-11 | Regeneron Pharmaceuticals, Inc. | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments |
| CN111592595B (zh) * | 2020-04-27 | 2021-02-19 | 南京医科大学 | 抗新型冠状病毒SARS-Cov-2的中和性抗体及其应用 |
-
2021
- 2021-10-08 EP EP21876827.3A patent/EP4225804A4/en active Pending
- 2021-10-08 AU AU2021356355A patent/AU2021356355A1/en active Pending
- 2021-10-08 US US18/030,944 patent/US20250263469A1/en active Pending
- 2021-10-08 BR BR112023006497A patent/BR112023006497A2/pt unknown
- 2021-10-08 MX MX2023004023A patent/MX2023004023A/es unknown
- 2021-10-08 CA CA3197642A patent/CA3197642A1/en active Pending
- 2021-10-08 JP JP2023521536A patent/JP2023544211A/ja active Pending
- 2021-10-08 WO PCT/CA2021/051426 patent/WO2022073138A1/en not_active Ceased
- 2021-10-08 KR KR1020237015177A patent/KR20230083316A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022073138A1 (en) | 2022-04-14 |
| EP4225804A1 (en) | 2023-08-16 |
| AU2021356355A1 (en) | 2023-05-25 |
| EP4225804A4 (en) | 2025-07-02 |
| CA3197642A1 (en) | 2022-04-14 |
| US20250263469A1 (en) | 2025-08-21 |
| KR20230083316A (ko) | 2023-06-09 |
| JP2023544211A (ja) | 2023-10-20 |
| BR112023006497A2 (pt) | 2023-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023004023A (es) | Polipéptidos que eligen como objetivo a sars-cov-2 y composiciones y métodos relacionados. | |
| CO5601037A2 (es) | Anticuerpos anti-a beta y sus usos | |
| Lehtonen et al. | Parietal and visceral endoderm differ in their expression of intermediate filaments. | |
| Holton et al. | Desmosomal glycoproteins 2 and 3 (desmocollins) show N-terminal similarity to calcium-dependent cell-cell adhesion molecules | |
| MX2021011330A (es) | Anticuerpos de claudina-6 y conjugados de fármacos. | |
| AR079114A1 (es) | Proteinas de enlace de antigenos anti-orai1 y usos de las mismas | |
| BR112022024063A2 (pt) | Polipeptídeos de coronavírus 2 da síndrome respiratória aguda grave (sars-cov-2) e usos dos mesmos para fins de vacina | |
| AR123206A1 (es) | Terapia génica | |
| AR042968A1 (es) | Anticuerpos de virus anti-dengue composiciones metodos y usos | |
| AR126556A1 (es) | Anticuerpos de dominios fc heterodiméricos | |
| BR112023017749A2 (pt) | Composições incluindo adjuvantes sbi e métodos de uso das mesmas | |
| CO2023000048A2 (es) | Conjugados de citoquina | |
| Gigi‐Leitner et al. | Antigenic interrelationship between the 40‐kilodalton cytokeratin polypeptide and desmoplakins | |
| MX2024004462A (es) | Composiciones y métodos para la edición del genoma del receptor fc neonatal. | |
| AR027765A1 (es) | Expresion y purificacion de polipeptidos bioactivos autenticos a partir de plantas | |
| CO4600642A1 (es) | Proteina globulina 11s, utilizable como marcador de imbibicion de una semilla en el curso de la germinacion | |
| PE20241789A1 (es) | Anticuerpos anti-clec12a y usos de los mismos | |
| CO2023017358A2 (es) | Formulaciones de proteínas quiméricas del factor viii y usos de las mismas | |
| PE20252244A1 (es) | Proteinas de fusion fc de il-12 | |
| CL2024003295A1 (es) | Ácido nucleico aislado que codifica proteína de fusión basada en fviii-bdd y péptido señal heterólogo | |
| PE20251544A1 (es) | Nueva proteina de fusion especifica para cd137 y cd228 | |
| AR127445A1 (es) | Anticuerpos de unión a claudina 18.2 y fragmentos de estos | |
| CO2024013909A2 (es) | Polipéptidos de fusión sirp-alfa con dominios fc modificados | |
| PE20251108A1 (es) | Anticuerpo monoclonal o fragmento de union al antigeno del mismo que se une especificamente a bcma, y uso del mismo | |
| AR133583A1 (es) | Métodos para tratar trastornos de la sangre con anticuerpos monoespecíficos dirigidos a vwf |